1. Diabetic Dyslipidemia in Practice

3. Risk of CVD in Patients With Diabetic Dyslipidemia

4. People With Diabetes Have a Twofold to Threefold Increased Risk of Heart Disease

5. Incorporating Guidelines Into Clinical Practice

6. Treating Patients Who Have Diabetes With Statins

7. The Role of Nonstatin Therapy

8. Patients at High Risk Are Not Reaching Targets

9. A Review of PCSK9 Inhibitors

10. The Importance of the ODYSSEY DM-INSULIN Trial

11. ODYSSEY DM-INSULIN Trial

12. ODYSSEY DM-INSULIN Trial HbA1c and Glucose Levels

13. The Importance of the ODYSSEY DM-DYSLIPIDEMIA Trial

14. ODYSSEY DM-DYSLIPIDEMIA Trial

15. CVOT Data on PCSK9 Inhibitor Evolocumab in Patients: FOURIER Trial

16. Upcoming CVOT Data on PCSK9 Inhibitors in Patients: ODYSSEY OUTCOMES

17. Implications for Clinical Practice How to Treat Patients at Risk?

18. Educating Patients on Use of PCSK9 Inhibitors

19. Role of Multispecialty Care for Effective Treatment

20. Concluding Remarks

21. Abbreviations

22. Abbreviations (cont)